Ibrexafungerp Versus Placebo for Vulvovaginal Candidiasis Treatment: A Phase 3, Randomized, Controlled Superiority Trial (VANISH 303)

202176 citationsJournal Articlebronze Open Access

Authors

Jane R. Schwebke · University of Alabama at Birmingham

Ryan Sobel · Thomas Jefferson University

Janet Gersten · Advanced Medical Research Institute

Steven A. Sussman

Samuel Lederman

Mark Jacobs

B. Todd Chappell · Memphis VA Medical Center

David Weinstein

Alfred H. Moffett

Abstract

Ibrexafungerp provides a promising safe and efficacious oral treatment that mechanistically differs from current azole treatment options for acute VVC.

Topics & Keywords

Nail Diseases and Treatments Reproductive tract infections research Antifungal resistance and susceptibility

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Clinical Infectious Diseases

Volume 74, Issue 11, pp. 1979-1985

DOI: 10.1093/cid/ciab750

Field-Weighted Citation Impact: 8.36